达格列净对射血分数轻度降低或保留心衰患者总心衰事件的影响:DELIVER 试验预设分析
本分析基于 DELIVER 试验 6263 例射血分数轻度降低或保留的心衰患者,评估达格列净 10 mg 每日一次对总心衰事件(首次及复发)与心血管死亡的影响。LWYY 模型显示,达格列净组总心衰事件与心血管死亡的率比为 0.77(95%CI 0.67-0.89,P<.001);关节 frailty 模型中总心衰事件率比为 0.72(95%CI 0.65-0.81,P<.001),心血管死亡率比为 0.87(95%CI 0.72-1.05,P=.14)。各亚组(包括按射血分数划分)结果一致。
要点
- 达格列净降低总心衰事件(首次及复发)与心血管死亡的复合终点率比 0.77。
- 关节 frailty 模型中总心衰事件率比 0.72,心血管死亡率比 0.87 未达统计学显著。
- 包括射血分数在内的各亚组结果一致,提示获益不受患者特征影响。
核心结论
- 在 DELIVER 试验中,达格列净降低总心衰事件(首次及后续心衰住院和紧急心衰就诊)与心血管死亡的速率,且不受包括射血分数在内的患者特征影响。
研究设计与样本
- DELIVER 试验的预设分析,纳入 6263 例射血分数轻度降低或保留的心衰患者,女性 2747 例(43.9%),平均(SD)年龄 71.7(9.6)岁。
- 采用 Lin-Wei-Yang-Ying(LWYY)比例率法和关节 frailty 模型分析达格列净对总心衰事件与心血管死亡的影响,并检查包括左心室射血分数在内的多个亚组。
主要发现
- 安慰剂组共 1057 例心衰事件和心血管死亡,达格列净组 815 例。
- 心衰事件更多的患者具有更严重心衰特征,如更高的 N 末端 B 型利钠肽原水平、更差的肾功能、更多既往心衰住院和更长心衰病程,但射血分数与无心衰事件者相似。
- LWYY 模型中达格列净对比安慰剂的总心衰事件与心血管死亡率比为 0.77(95%CI 0.67-0.89,P<.001),传统首次事件分析的风险比为 0.82(95%CI 0.73-0.92,P<.001)。
- 关节 frailty 模型中总心衰事件率比为 0.72(95%CI 0.65-0.81,P<.001),心血管死亡率比为 0.87(95%CI 0.72-1.05,P=.14)。
- 总心衰住院(不含紧急心衰就诊)与心血管死亡的结果及包括按射血分数定义的各亚组结果均相似。
关键数值与推荐
- 达格列净 10 mg 每日一次。
- LWYY 模型总心衰事件与心血管死亡率比 0.77(95%CI 0.67-0.89,P<.001)。
- 传统首次事件分析风险比 0.82(95%CI 0.73-0.92,P<.001)。
- 关节 frailty 模型总心衰事件率比 0.72(95%CI 0.65-0.81,P<.001),心血管死亡率比 0.87(95%CI 0.72-1.05,P=.14)。
临床怎么用
- 对射血分数轻度降低或保留的心衰患者,达格列净可减少总心衰事件(含复发事件),支持将其用于降低心衰事件负担。
- 分析总心衰事件时采用 LWYY 或关节 frailty 模型可更全面反映复发事件的治疗效应,率比数值低于传统首次事件风险比。
局限性
- 本分析为 DELIVER 试验的预设分析,其结果解释应结合该试验的整体设计与人群。
- 关节 frailty 模型中达格列净对心血管死亡的效应未达统计学显著(P=.14)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: In the Dapagliflozin Evaluation to Improve the Lives of Patients With Preserved Ejection Fraction Heart Failure (DELIVER) trial, dapagliflozin reduced the risk of time to first worsening heart failure (HF) event or cardiovascular death in patients with HF with mildly reduced or preserved ejection fraction (EF). OBJECTIVE: To evaluate the effect of dapagliflozin on total (ie, first and recurrent) HF events and cardiovascular death in this population. DESIGN, SETTING, AND PARTICIPANTS: In this prespecified analysis of the DELIVER trial, the proportional rates approach of Lin, Wei, Yang, and Ying (LWYY) and a joint frailty model were used to examine the effect of dapagliflozin on total HF events and cardiovascular death. Several subgroups were examined to test for heterogeneity in the effect of dapagliflozin, including left ventricular EF. Participants were enrolled from August 2018 to December 2020, and data were analyzed from August to October 2022. INTERVENTIONS: Dapagliflozin, 10 mg, once daily or matching placebo. MAIN OUTCOMES AND MEASURES: The outcome was total episodes of worsening HF (hospitalization for HF or urgent HF visit requiring intravenous HF therapies) and cardiovascular death. RESULTS: Of 6263 included patients, 2747 (43.9%) were women, and the mean (SD) age was 71.7 (9.6) years. There were 1057 HF events and cardiovascular deaths in the placebo group compared with 815 in the dapagliflozin group. Patients with more HF events had features of more severe HF, such as higher N-terminal pro-B-type natriuretic peptide level, worse kidney function, more prior HF hospitalizations, and longer duration of HF, although EF was similar to those with no HF events. In the LWYY model, the rate ratio for total HF events and cardiovascular death for dapagliflozin compared with placebo was 0.77 (95% CI, 0.67-0.89; P < .001) compared with a hazard ratio of 0.82 (95% CI, 0.73-0.92; P < .001) in a traditional time to first event analysis. In the joint frailty model, the rate ratio was 0.72 (95% CI, 0.65-0.81; P < .001) for total HF events and 0.87 (95% CI, 0.72-1.05; P = .14) for cardiovascular death. The results were similar for total HF hospitalizations (without urgent HF visits) and cardiovascular death and in all subgroups, including those defined by EF. CONCLUSIONS AND RELEVANCE: In the DELIVER trial, dapagliflozin reduced the rate of total HF events (first and subsequent HF hospitalizations and urgent HF visits) and cardiovascular death regardless of patient characteristics, including EF. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT03619213.
引用
- Jhund, Claggett, Talebi, et al. Effect of Dapagliflozin on Total Heart Failure Events in Patients With Heart Failure With Mildly Reduced or Preserved Ejection Fraction: A Prespecified Analysis of the DELIVER Trial. JAMA Cardiol. 2023. PMID: 37099283. doi:10.1001/jamacardio.2023.0711
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。